

---

## MEDIA RELEASE

---

### **Teva launches Copaxone® with the YpsoMate® autoinjector from Ypsomed**

**Burgdorf, 07.05.2019, 7.00 a.m. – Teva Pharmaceutical Industries Ltd. (Teva), a global leader in generic medicines with innovative treatments in select areas, including CNS, pain and respiratory, has launched its drug product Copaxone® in the pre-filled autoinjector YpsoMate® from Ypsomed. Copaxone® is used for the treatment of patients with relapsing forms of multiple sclerosis (MS). The collaboration with Teva marks the second commercial market entry of Ypsomed's autoinjector YpsoMate®.**

Copaxone® (glatiramer acetate injection) is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS). The Copaxone® brand is approved in more than 50 countries worldwide, including the United States, Russia, Canada, Mexico, Australia, Israel and all European countries. To date, Teva has mainly marketed Copaxone® in a standard syringe. With the launch of the drug in an autoinjector, Teva offers Copaxone® now in an easy-to-use and easy-to-handle device, making self-medication for patients living with MS easier and more convenient. According to the World Health Organization (WHO), more than 2.3 million people are affected by MS worldwide.

Teva has already launched Copaxone® in combination with the YpsoMate® in Germany in March 2019 and will launch in other markets within the next few months. The pre-filled autoinjector is based on Ypsomed's YpsoMate® platform and is designed for subcutaneous injection of liquid drugs. Teva opted for the 1.0 ml variant of the autoinjector with Teva specific colours of the device.

"The broad interest of leading pharma partners in our autoinjectors proves that we are meeting market needs. Our platform approach allows us to fulfil the individual needs of our customers in a short time while remaining flexible in production capacities," comments Ulrike Bauer, Senior Vice President Delivery Systems, the success of the autoinjector.

For further information, please contact Thomas Kutt, Head of Investor Relations at Ypsomed Holding AG, at the telephone number +41 34 424 35 55 or by e-mail ([thomas.kutt@ypsomed.com](mailto:thomas.kutt@ypsomed.com)).

### **About the Ypsomed Group**

The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years' experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylife™ Diabetescare directly to patients or through pharmacies and clinics and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs almost 1'600 employees. Additional information is available under [www.ypsomed.com](http://www.ypsomed.com).

### **About Teva**

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global leader in generic medicines, with innovative treatments in select areas, including CNS, pain and respiratory. Teva delivers high-quality generic products and medicines in nearly every therapeutic area to address unmet patient needs. Teva has an established presence in generics, specialty, OTC and API, building on more than a century-old legacy, with a fully integrated R&D function, strong operational base and global infrastructure and scale. Teva strives to act in a socially and environmentally responsible way. Headquartered in Israel, with production and research facilities around the globe, they employ 43,000 professionals, committed to improving the lives of millions of patients. Learn more at [www.tevapharm.com](http://www.tevapharm.com).